Sabine Mainbourg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sabine Mainbourg has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Christophe Lega
Laboratoire de Biométrie et Biologie Evolutive UMR 5558, CNRS Université Lyon 1, Université de Lyon Villeurbanne France
7 shared publications - Hervé Lobbes
Service de Médecine Interne, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
6 shared publications Maxime Samson
CHU Dijon Bourgogne, Hop Francois Mitterrand, Serv Med Interne & Immunol Clin, Dijon, France
3 shared publications- Anaïs Lacasse
Université du Québec en Abitibi-Témiscamingue
2 shared publications - Anick Bérard
Research Center, CHU Sainte-Justine, Montreal, Canada
2 shared publications - Anne Monique Nuyt
Research Center CHU Ste-Justine, Montreal, QC H3T 1C5, Canada
2 shared publications
Latest Publications
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Morbimortality in giant cell arteritis and the impact of therapeutics
Morbi-mortalité de l’artérite à cellules géantes et impact des thérapeutiques: L’artérite à cellules géantes (ACG) est une inflammation des parois des gros et moyens vaisseaux et concerne les adultes de plus de 50 ans. Elle se manifeste par des céphalées, une altération de l’état général et un syndrome inflammatoire biologique. Des complications sévères peuvent survenir. La corticothérapie est la pierre angulaire du traitement, mais entraîne de nombreuses complications lors d’une prise prolongée. L’objectif de ce travail était de faire l’état des lieux de la morbi-mortalité de la pathologie, à partir des données publiées, et des données de mortalité disponibles via EUROSTAT ; d’évaluer l’intérêt relatif en terme d’efficacité et de tolérance des molécules à visée d’épargne cortisonique actuellement disponibles. Une revue de la littérature de l’ACG a été réalisée. La prévalence des rechutes a été estimée par des techniques méta-analytiques. 34 études ont été inclues totalisant 2 505 patients. La prévalence globale était estimée à 47,2% (intervalle de confiance (IC) à 95% 40,0 – 54,3), avec une forte hétérogénéité (I²=93%). La prévalence des rechutes était significativement plus haute dans les essais randomisés par rapport aux études observationnelles (65,8% versus 41,7%, p<0.0001). La prévalence des rechutes était également associée à l’année de publication (34 études, augmentation de 8.3% par décade; p<0.0001) et à la durée de la corticothérapie (17 études, diminution de 1.7% pour chaque mois supplémentaire; p<0.001). La prévalence et l’incidence des rechutes sévères ont été estimées par une méta-analyse. 26 études ont été inclues, totalisant 2 754 patients. La prévalence des rechutes majeures était estimée à 3,3% (IC 95% 1,7 – 5,6; I²=86%) et l’incidence à 14,5/100 patient-année (IC 95% 5,2 – 27,2; I²=90%). Les manifestations cliniques étaient les claudications de la mâchoire (44,3%), les atteintes ophtalmologiques (32,7%). Lors de la méta-régression, la durée de suivi était inversement corrélée à l’incidence des rechutes majeures (Beta = -0.015, IC 95% -0,026 – -0,0042; p=0,0063). Une analyse a été conduite sur les données de mortalité liée à l’ACG en Europe (Eurostat). Les données de mortalité concernant l’ACG ont été extraites entre 1994 et 2016. Les données ont été extraites pour 31 pays européens : les 27 membres de l’Union Européenne, 3 pays membres de l’association européenne de libre-échange, et le Royaume-Uni. Les populations ont été agrégées par tranche de 5 ans, entre 50 ans et plus de 85 ans. Les taux bruts et les taux de mortalité normalisés selon l’âge (ASMR) ont été calculés. Entre 1994 et 2016, 5650 décès ont été rapportés à l’ACG. L’ASMR européen variait de 0,436/100 000 population (IC 95% 0,384 – 0,494) en 1994 à 0,146/100 000 population (IC 95% 0,130 – 0,163) en 2016 et diminuait significativement au cours du temps (-0,017 par an, p<0,001). Les différents traitements proposés dans l’ACG ont été comparés par une méta-analyse en réseau incluant les essais randomisés contrôlés dans l’ACG. La recherche a été effectuée sur MedLine et ClinicalTrial.gov. Le critère de jugement principal était le taux de rechute. 8 essais ont été inclus, totalisant 572 patients. Tous les essais comparaient un traitement d’épargne cortisonique avec une corticothérapie. La certitude de la preuve a été établie en utilisant la méthode GRADE. Le niveau de preuve était faible ou très faible pour les comparaisons d’intérêt. Le risque de rechute était significativement plus faible avec le tocilizumab comparé au méthotrexate (RR=0,41; IC 95% 0,17 – 0,97), à la corticothérapie prolongée (RR=0,41, IC 95% 0,20 – 0,83), et à la corticothérapie courte (RR=0,32; IC 95% 0,16 – 0,66). Les fréquences d’effets indésirables sévères et d’infections sévères étaient comparables entre les différents traitements. L’ensemble des travaux réalisés ici propose un modèle de connaissance de l’ACG, qui permettra de construire un modèle computationnel, lui-même étant le point de départ de la construction d’une population virtuelle réaliste.
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Morbimortality in giant cell arteritis and the impact of therapeutics
Morbi-mortalité de l’artérite à cellules géantes et impact des thérapeutiques: L’artérite à cellules géantes (ACG) est une inflammation des parois des gros et moyens vaisseaux et concerne les adultes de plus de 50 ans. Elle se manifeste par des céphalées, une altération de l’état général et un syndrome inflammatoire biologique. Des complications sévères peuvent survenir. La corticothérapie est la pierre angulaire du traitement, mais entraîne de nombreuses complications lors d’une prise prolongée. L’objectif de ce travail était de faire l’état des lieux de la morbi-mortalité de la pathologie, à partir des données publiées, et des données de mortalité disponibles via EUROSTAT ; d’évaluer l’intérêt relatif en terme d’efficacité et de tolérance des molécules à visée d’épargne cortisonique actuellement disponibles. Une revue de la littérature de l’ACG a été réalisée. La prévalence des rechutes a été estimée par des techniques méta-analytiques. 34 études ont été inclues totalisant 2 505 patients. La prévalence globale était estimée à 47,2% (intervalle de confiance (IC) à 95% 40,0 – 54,3), avec une forte hétérogénéité (I²=93%). La prévalence des rechutes était significativement plus haute dans les essais randomisés par rapport aux études observationnelles (65,8% versus 41,7%, p<0.0001). La prévalence des rechutes était également associée à l’année de publication (34 études, augmentation de 8.3% par décade; p<0.0001) et à la durée de la corticothérapie (17 études, diminution de 1.7% pour chaque mois supplémentaire; p<0.001). La prévalence et l’incidence des rechutes sévères ont été estimées par une méta-analyse. 26 études ont été inclues, totalisant 2 754 patients. La prévalence des rechutes majeures était estimée à 3,3% (IC 95% 1,7 – 5,6; I²=86%) et l’incidence à 14,5/100 patient-année (IC 95% 5,2 – 27,2; I²=90%). Les manifestations cliniques étaient les claudications de la mâchoire (44,3%), les atteintes ophtalmologiques (32,7%). Lors de la méta-régression, la durée de suivi était inversement corrélée à l’incidence des rechutes majeures (Beta = -0.015, IC 95% -0,026 – -0,0042; p=0,0063). Une analyse a été conduite sur les données de mortalité liée à l’ACG en Europe (Eurostat). Les données de mortalité concernant l’ACG ont été extraites entre 1994 et 2016. Les données ont été extraites pour 31 pays européens : les 27 membres de l’Union Européenne, 3 pays membres de l’association européenne de libre-échange, et le Royaume-Uni. Les populations ont été agrégées par tranche de 5 ans, entre 50 ans et plus de 85 ans. Les taux bruts et les taux de mortalité normalisés selon l’âge (ASMR) ont été calculés. Entre 1994 et 2016, 5650 décès ont été rapportés à l’ACG. L’ASMR européen variait de 0,436/100 000 population (IC 95% 0,384 – 0,494) en 1994 à 0,146/100 000 population (IC 95% 0,130 – 0,163) en 2016 et diminuait significativement au cours du temps (-0,017 par an, p<0,001). Les différents traitements proposés dans l’ACG ont été comparés par une méta-analyse en réseau incluant les essais randomisés contrôlés dans l’ACG. La recherche a été effectuée sur MedLine et ClinicalTrial.gov. Le critère de jugement principal était le taux de rechute. 8 essais ont été inclus, totalisant 572 patients. Tous les essais comparaient un traitement d’épargne cortisonique avec une corticothérapie. La certitude de la preuve a été établie en utilisant la méthode GRADE. Le niveau de preuve était faible ou très faible pour les comparaisons d’intérêt. Le risque de rechute était significativement plus faible avec le tocilizumab comparé au méthotrexate (RR=0,41; IC 95% 0,17 – 0,97), à la corticothérapie prolongée (RR=0,41, IC 95% 0,20 – 0,83), et à la corticothérapie courte (RR=0,32; IC 95% 0,16 – 0,66). Les fréquences d’effets indésirables sévères et d’infections sévères étaient comparables entre les différents traitements. L’ensemble des travaux réalisés ici propose un modèle de connaissance de l’ACG, qui permettra de construire un modèle computationnel, lui-même étant le point de départ de la construction d’une population virtuelle réaliste.
- 27 November 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (2) , 1171-1179
Characteristics of patients with major relapse in giant cell arteritis: a multicenter case–control study
Objectives The objective was to identify predictive factors for major relapses (MR) in patients with giant cell arteritis (GCA) and to compare clinical characteristics between MR phenotypes. Method This multicenter retrospective case–control study included patients fulfilling GiaCTA criteria for GCA. Cases were patients experiencing MR according to 2018 EULAR definitions. Controls were GCA patients without MR with a 1:3 ratio. Data were collected and analyzed using univariate and multivariate logistic regression to determine factors independently associated with MR. MR was subclassified into cranial-MR and large-vessel-MR which were compared using appropriate statistical tests. Results 258 patients were included, 70 cases and 188 controls (48.4% minor relapse, and 24.4% without relapse). The mean age at diagnosis was 72.5 ± 8.6 years, 70,9% were females. Younger age at diagnosis was associated with an increased risk of MR (OR = 0.93 per 10 years, 95% CI [0.87; 0.999], p = 0.043). No other clinically significant risk factors were identified. Among the 70 cases, 48.6% had a cranial-MR and 51.4% a large-vessel-MR. Patients with a cranial-MR were older (74.3 ± 6.3 years vs. 67.3 ± 7.0 years, p < 0.001) and were more likely to have cranial symptoms at diagnosis of GCA (91.2% vs. 69.4%, p = 0.023) compared to those with a large-vessel-MR. Compared with cranial-MR, large-vessel MR was more frequent in women (80.5% vs. 52.9%, p < 0.01) and tended to be associated with aortitis at diagnosis (70.0% vs. 43.5%, p = 0.052). Conclusions Younger age at diagnosis was the only independent predictor of MR. Relapse patterns mirrored initial disease phenotype, supporting the existence of cranial and large-vessel GCA subtypes. Key Points •Younger age at diagnosis is associated with a higher risk of major relapse in giant cell arteritis. •Cranial and large-vessel major relapses display distinct clinical patterns, often mirroring the initial disease phenotype. •No strong laboratory or imaging predictor of major relapse was identified in this multicentre case–control study.
- 27 November 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (2) , 1171-1179
Characteristics of patients with major relapse in giant cell arteritis: a multicenter case–control study
Objectives The objective was to identify predictive factors for major relapses (MR) in patients with giant cell arteritis (GCA) and to compare clinical characteristics between MR phenotypes. Method This multicenter retrospective case–control study included patients fulfilling GiaCTA criteria for GCA. Cases were patients experiencing MR according to 2018 EULAR definitions. Controls were GCA patients without MR with a 1:3 ratio. Data were collected and analyzed using univariate and multivariate logistic regression to determine factors independently associated with MR. MR was subclassified into cranial-MR and large-vessel-MR which were compared using appropriate statistical tests. Results 258 patients were included, 70 cases and 188 controls (48.4% minor relapse, and 24.4% without relapse). The mean age at diagnosis was 72.5 ± 8.6 years, 70,9% were females. Younger age at diagnosis was associated with an increased risk of MR (OR = 0.93 per 10 years, 95% CI [0.87; 0.999], p = 0.043). No other clinically significant risk factors were identified. Among the 70 cases, 48.6% had a cranial-MR and 51.4% a large-vessel-MR. Patients with a cranial-MR were older (74.3 ± 6.3 years vs. 67.3 ± 7.0 years, p < 0.001) and were more likely to have cranial symptoms at diagnosis of GCA (91.2% vs. 69.4%, p = 0.023) compared to those with a large-vessel-MR. Compared with cranial-MR, large-vessel MR was more frequent in women (80.5% vs. 52.9%, p < 0.01) and tended to be associated with aortitis at diagnosis (70.0% vs. 43.5%, p = 0.052). Conclusions Younger age at diagnosis was the only independent predictor of MR. Relapse patterns mirrored initial disease phenotype, supporting the existence of cranial and large-vessel GCA subtypes. Key Points •Younger age at diagnosis is associated with a higher risk of major relapse in giant cell arteritis. •Cranial and large-vessel major relapses display distinct clinical patterns, often mirroring the initial disease phenotype. •No strong laboratory or imaging predictor of major relapse was identified in this multicentre case–control study.
- Open Access
- 15 April 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 126, 69-76
Prognostic value of 18 FDG-PET at diagnosis and follow-up in giant cell arteritis: An observational restrospective study
- 15 April 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 126, 69-76
Open AccessPrognostic value of 18 FDG-PET at diagnosis and follow-up in giant cell arteritis: An observational restrospective study
- Open Access
- 26 October 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (21) , 6451-6465
Treatment strategy for acquired pure red cell aplasia: a systematic review and meta-analysis
The treatment of autoimmune acquired pure red cell aplasia (aPRCA) is challenging. Guidelines are based on expert recommendations in the absence of controlled trials. We assessed the efficacy of the main treatment strategy through a systematic review and meta-analysis using MEDLINE, EMBASE, and the Cochrane Library up to September 2022. The overall response rate (ORR) was pooled using random-effects models. In total, 24 observational studies (19 retrospective, median follow-up of 48 months) encompassing 753 patients (49% male) were included. Primary aPRCA represented 57% of the cases. The risk of bias was moderate to high using the ROBINS-I tool. Substantial heterogeneity (I2 > 50%) was retrieved. Corticosteroids as monotherapy as first-line treatment (186 patients, 13 studies) provided an ORR of 47% (95% confidence interval [CI], 34-60). Cyclosporine A was the most frequently used immunosuppressant agent (384 patients, 18 studies), providing an ORR of 74% (95% CI, 66-82) with a similar ORR in first- (73%) and second-line (76%) treatment and when cyclosporin was used as monotherapy (83%) or with corticosteroids (77%). A total of 112 patients (10 studies) received cyclophosphamide, with an ORR of 49% (95% CI, 35-64), which was higher when cyclophosphamide was combined with corticosteroids (48%) and used in second-line treatment (58%) than in monotherapy (31%), and in first-line treatment (44%). Sirolimus use was reported only after cyclosporine A failure and provided an ORR of 87% (95% CI, 68-100; 64 patients, 3 studies). Substantial uncertainty remains regarding the best treatment strategy in the absence of high-quality evidence. This study was registered on the PROPERO database as #CRD42022360452.
- 26 October 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (21) , 6451-6465
Open AccessTreatment strategy for acquired pure red cell aplasia: a systematic review and meta-analysis
The treatment of autoimmune acquired pure red cell aplasia (aPRCA) is challenging. Guidelines are based on expert recommendations in the absence of controlled trials. We assessed the efficacy of the main treatment strategy through a systematic review and meta-analysis using MEDLINE, EMBASE, and the Cochrane Library up to September 2022. The overall response rate (ORR) was pooled using random-effects models. In total, 24 observational studies (19 retrospective, median follow-up of 48 months) encompassing 753 patients (49% male) were included. Primary aPRCA represented 57% of the cases. The risk of bias was moderate to high using the ROBINS-I tool. Substantial heterogeneity (I2 > 50%) was retrieved. Corticosteroids as monotherapy as first-line treatment (186 patients, 13 studies) provided an ORR of 47% (95% confidence interval [CI], 34-60). Cyclosporine A was the most frequently used immunosuppressant agent (384 patients, 18 studies), providing an ORR of 74% (95% CI, 66-82) with a similar ORR in first- (73%) and second-line (76%) treatment and when cyclosporin was used as monotherapy (83%) or with corticosteroids (77%). A total of 112 patients (10 studies) received cyclophosphamide, with an ORR of 49% (95% CI, 35-64), which was higher when cyclophosphamide was combined with corticosteroids (48%) and used in second-line treatment (58%) than in monotherapy (31%), and in first-line treatment (44%). Sirolimus use was reported only after cyclosporine A failure and provided an ORR of 87% (95% CI, 68-100; 64 patients, 3 studies). Substantial uncertainty remains regarding the best treatment strategy in the absence of high-quality evidence. This study was registered on the PROPERO database as #CRD42022360452.
- Open Access
- 28 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 12386
The Impact of COVID-19 on Maternal Mental Health during Pregnancy: A Comparison between Canada and China within the CONCEPTION Cohort
The effect of the COVID-19 pandemic on maternal mental health has been described in Canada and China but no study has compared the two countries using the same standardized and validated instruments. In this study, we aimed to evaluate and compare the impact of COVID-19 public health policies on maternal mental health between Canada and China, as we hypothesize that geographical factors and different COVID-19 policies are likely to influence maternal mental health. Pregnant persons >18 years old were recruited in Canada and China using a web-based strategy. All participants recruited between 26 June 2020 and 16 February 2021 were analyzed. Self-reported data included sociodemographic variables, COVID-19 experience and maternal mental health assessments (Edinburgh Perinatal Depression Scale (EPDS), Generalized Anxiety Disorders (GAD-7) scale, stress and satisfaction with life). Analyses were stratified by recruitment cohort, namely: Canada 1 (26 June 2020–10 October 2020), Canada 2 and China (11 October 2020–16 February 2021). Overall, 2423 participants were recruited, with 1804 participants within Canada 1, 135 within Canada 2 and 484 in China. The mean EDPS scores were 8.1 (SD, 5.1) in Canada 1, 8.1 (SD, 5.2) in Canada 2 and 7.7 (SD, 4.9) in China (p-value Canada 2/China: p = 0.005). The mean GAD-7 scores were 2.6 (SD, 2.9) in China, 4.3 (SD, 3.8) in Canada 1 (p < 0.001) and 5.8 (SD, 5.2) in Canada 2 (p < 0.001). When adjusting for stress and anxiety, being part of the Chinese cohort significantly increased the chances of having maternal depression by over threefold (adjusted OR 3.20, 95%CI 1.77–5.78). Canadian and Chinese participants reported depressive scores nearly double those of other crises and non-pandemic periods. Lockdowns and reopening periods have an important impact on levels of depression and anxiety among pregnant persons.
- 28 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 12386
Open AccessThe Impact of COVID-19 on Maternal Mental Health during Pregnancy: A Comparison between Canada and China within the CONCEPTION Cohort
The effect of the COVID-19 pandemic on maternal mental health has been described in Canada and China but no study has compared the two countries using the same standardized and validated instruments. In this study, we aimed to evaluate and compare the impact of COVID-19 public health policies on maternal mental health between Canada and China, as we hypothesize that geographical factors and different COVID-19 policies are likely to influence maternal mental health. Pregnant persons >18 years old were recruited in Canada and China using a web-based strategy. All participants recruited between 26 June 2020 and 16 February 2021 were analyzed. Self-reported data included sociodemographic variables, COVID-19 experience and maternal mental health assessments (Edinburgh Perinatal Depression Scale (EPDS), Generalized Anxiety Disorders (GAD-7) scale, stress and satisfaction with life). Analyses were stratified by recruitment cohort, namely: Canada 1 (26 June 2020–10 October 2020), Canada 2 and China (11 October 2020–16 February 2021). Overall, 2423 participants were recruited, with 1804 participants within Canada 1, 135 within Canada 2 and 484 in China. The mean EDPS scores were 8.1 (SD, 5.1) in Canada 1, 8.1 (SD, 5.2) in Canada 2 and 7.7 (SD, 4.9) in China (p-value Canada 2/China: p = 0.005). The mean GAD-7 scores were 2.6 (SD, 2.9) in China, 4.3 (SD, 3.8) in Canada 1 (p < 0.001) and 5.8 (SD, 5.2) in Canada 2 (p < 0.001). When adjusting for stress and anxiety, being part of the Chinese cohort significantly increased the chances of having maternal depression by over threefold (adjusted OR 3.20, 95%CI 1.77–5.78). Canadian and Chinese participants reported depressive scores nearly double those of other crises and non-pandemic periods. Lockdowns and reopening periods have an important impact on levels of depression and anxiety among pregnant persons.
- Open Access
- 16 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (18) , 5438
Extreme Hyperferritinemia: Causes and Prognosis
The significance of extreme hyperferritinemia and its association with certain diagnoses and prognoses are not well characterized. We performed a retrospective analysis of adult patients with at least one total serum ferritin (TSF) measurement ≥ 5000 µg/L over 2 years, in three university hospitals. Conditions associated with hyperferritinemia were collected, and patients were classified into 10 etiological groups. Intensive care unit (ICU) transfer and mortality rates were recorded. A total of 495 patients were identified, of which 56% had a TSF level between 5000 and 10,000 µg/L. There were multiple underlying causes in 81% of the patients. The most common causes were infections (38%), hemophagocytic lymphohistiocytosis (HLH, 18%), and acute hepatitis (14%). For TSF levels > 10,000 µg/L, there were no solid cancer or hematological malignancy without another cause of hyperferritinemia. Isolated iron-overload syndromes never exceeded TSF levels > 15,000 µg/L. Extreme hyperferritinemia (TSF levels > 25,000 µg/L) was associated with only four causes: HLH, infections, acute hepatitis and cytokine release syndromes. A total of 32% of patients were transferred to an ICU, and 28% died. Both ICU transfer rate and mortality were statistically associated with ferritin levels. An optimized threshold of 13,405 μg/L was the best predictor for the diagnosis of HLH, with a sensitivity of 76.4% and a specificity of 79.3%. Hyperferritinemia reflects a variety of conditions, but only four causes are associated with extreme hyperferritinemia, in which HLH and acute hepatitis are the most common. Extreme hyperferritinemia has a poor prognosis with increased mortality.
- 16 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (18) , 5438
Open AccessExtreme Hyperferritinemia: Causes and Prognosis
The significance of extreme hyperferritinemia and its association with certain diagnoses and prognoses are not well characterized. We performed a retrospective analysis of adult patients with at least one total serum ferritin (TSF) measurement ≥ 5000 µg/L over 2 years, in three university hospitals. Conditions associated with hyperferritinemia were collected, and patients were classified into 10 etiological groups. Intensive care unit (ICU) transfer and mortality rates were recorded. A total of 495 patients were identified, of which 56% had a TSF level between 5000 and 10,000 µg/L. There were multiple underlying causes in 81% of the patients. The most common causes were infections (38%), hemophagocytic lymphohistiocytosis (HLH, 18%), and acute hepatitis (14%). For TSF levels > 10,000 µg/L, there were no solid cancer or hematological malignancy without another cause of hyperferritinemia. Isolated iron-overload syndromes never exceeded TSF levels > 15,000 µg/L. Extreme hyperferritinemia (TSF levels > 25,000 µg/L) was associated with only four causes: HLH, infections, acute hepatitis and cytokine release syndromes. A total of 32% of patients were transferred to an ICU, and 28% died. Both ICU transfer rate and mortality were statistically associated with ferritin levels. An optimized threshold of 13,405 μg/L was the best predictor for the diagnosis of HLH, with a sensitivity of 76.4% and a specificity of 79.3%. Hyperferritinemia reflects a variety of conditions, but only four causes are associated with extreme hyperferritinemia, in which HLH and acute hepatitis are the most common. Extreme hyperferritinemia has a poor prognosis with increased mortality.
- 20 August 2022
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 97 (10) , 1824-1835
Indirect Comparison of Glucocorticoid-Sparing Agents for Remission Maintenance in Giant Cell Arteritis: A Network Meta-analysis
- 20 August 2022
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 97 (10) , 1824-1835
Indirect Comparison of Glucocorticoid-Sparing Agents for Remission Maintenance in Giant Cell Arteritis: A Network Meta-analysis
- Open Access
- 2 March 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (5) , 2926
The COVID-19 Pandemic Impacted Maternal Mental Health Differently Depending on Pregnancy Status and Trimester of Gestation
Introduction: We aimed to measure the impact of the COVID-19 pandemic on maternal mental health, stratifying on pregnancy status, trimester of gestation, and pandemic period/wave. Methods: Pregnant persons and persons who delivered in Canada during the pandemic, >18 years, were recruited, and data were collected using a web-based strategy. The current analysis includes data on persons enrolled between 06/2020–08/2021. Maternal sociodemographic indicators, mental health measures (Edinburgh Perinatal Depression Scale (EPDS), Generalized Anxiety Disorders (GAD-7), stress) were self-reported. Maternal mental health in pregnant women (stratified by trimester, and pandemic period/wave at recruitment) was compared with the mental health of women who had delivered; determinants of severe depression were identified with multivariate logistic regression models. Results: 2574 persons were pregnant and 626 had already delivered at recruitment. Participants who had delivered had significantly higher mean depressive symptom scores compared to those pregnant at recruitment (9.1 (SD, 5.7) vs. 8.4 (SD, 5.3), p = 0.009). Maternal anxiety (aOR 1.51; 95%CI 1.44–1.59) and stress (aOR 1.35; 95%CI 1.24–1.48) were the most significant predictors of severe maternal depression (EDPS ˃ 13) in pregnancy. Conclusion: The COVID-19 pandemic had a significant impact on maternal depression during pregnancy and in the post-partum period. Given that gestational depression/anxiety/stress has been associated with preterm birth and childhood cognitive problems, it is essential to continue following women/children, and develop strategies to reduce COVID-19′s longer-term impact.
- 2 March 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (5) , 2926
Open AccessThe COVID-19 Pandemic Impacted Maternal Mental Health Differently Depending on Pregnancy Status and Trimester of Gestation
Introduction: We aimed to measure the impact of the COVID-19 pandemic on maternal mental health, stratifying on pregnancy status, trimester of gestation, and pandemic period/wave. Methods: Pregnant persons and persons who delivered in Canada during the pandemic, >18 years, were recruited, and data were collected using a web-based strategy. The current analysis includes data on persons enrolled between 06/2020–08/2021. Maternal sociodemographic indicators, mental health measures (Edinburgh Perinatal Depression Scale (EPDS), Generalized Anxiety Disorders (GAD-7), stress) were self-reported. Maternal mental health in pregnant women (stratified by trimester, and pandemic period/wave at recruitment) was compared with the mental health of women who had delivered; determinants of severe depression were identified with multivariate logistic regression models. Results: 2574 persons were pregnant and 626 had already delivered at recruitment. Participants who had delivered had significantly higher mean depressive symptom scores compared to those pregnant at recruitment (9.1 (SD, 5.7) vs. 8.4 (SD, 5.3), p = 0.009). Maternal anxiety (aOR 1.51; 95%CI 1.44–1.59) and stress (aOR 1.35; 95%CI 1.24–1.48) were the most significant predictors of severe maternal depression (EDPS ˃ 13) in pregnancy. Conclusion: The COVID-19 pandemic had a significant impact on maternal depression during pregnancy and in the post-partum period. Given that gestational depression/anxiety/stress has been associated with preterm birth and childhood cognitive problems, it is essential to continue following women/children, and develop strategies to reduce COVID-19′s longer-term impact.
- Open Access
Iron Deficiency in Cystic Fibrosis: A Cross-Sectional Single-Centre Study in a Referral Adult Centre
Iron deficiency (ID) diagnosis in cystic fibrosis (CF) is challenging because of frequent systemic inflammation. We aimed to determine the prevalence and risk factors of ID in adult patients with CF. We conducted a single-centre prospective study in a referral centre. ID was defined by transferrin saturation ≤16% or ferritin ≤20 (women) or 30 (men) μg/L, or ≤100 μg/L in the case of systemic inflammation. Apparent exacerbation was an exclusion criterion. We included 165 patients (78 women), mean age—31.1 ± 8.9 years. ID prevalence was 44.2%. ID was significantly associated with female gender (58.9% vs. 38%), lower age (29.4 ± 8.5 vs. 32.5 ± 9.1), lower body mass index (20.5 ± 2.2 vs. 21.3 ± 2.5), and Pseudomonas aeruginosa colonization (70.8% vs. 55.1%). Diabetes mellitus, antiacid drug use and low pulmonary function were more frequent in patients with ID with no statistical significance. The use of CFTR correctors was not associated with ID. In the multivariate analysis, ID was associated with female gender (OR 2.64, CI95% 1.31–5.31), age < 30 years (OR 2.30, CI95% 1.16–4.56), and P. aeruginosa (OR 2.09, CI95% 1.04–4.19).
Open AccessIron Deficiency in Cystic Fibrosis: A Cross-Sectional Single-Centre Study in a Referral Adult Centre
Iron deficiency (ID) diagnosis in cystic fibrosis (CF) is challenging because of frequent systemic inflammation. We aimed to determine the prevalence and risk factors of ID in adult patients with CF. We conducted a single-centre prospective study in a referral centre. ID was defined by transferrin saturation ≤16% or ferritin ≤20 (women) or 30 (men) μg/L, or ≤100 μg/L in the case of systemic inflammation. Apparent exacerbation was an exclusion criterion. We included 165 patients (78 women), mean age—31.1 ± 8.9 years. ID prevalence was 44.2%. ID was significantly associated with female gender (58.9% vs. 38%), lower age (29.4 ± 8.5 vs. 32.5 ± 9.1), lower body mass index (20.5 ± 2.2 vs. 21.3 ± 2.5), and Pseudomonas aeruginosa colonization (70.8% vs. 55.1%). Diabetes mellitus, antiacid drug use and low pulmonary function were more frequent in patients with ID with no statistical significance. The use of CFTR correctors was not associated with ID. In the multivariate analysis, ID was associated with female gender (OR 2.64, CI95% 1.31–5.31), age < 30 years (OR 2.30, CI95% 1.16–4.56), and P. aeruginosa (OR 2.09, CI95% 1.04–4.19).
- 1 January 2022
- Published by Elsevier in Autoimmunity Reviews
- Vol. 21 (1) , 102930
Epidemiology of major relapse in giant cell arteritis: A study-level meta-analysis
- 1 January 2022
- Published by Elsevier in Autoimmunity Reviews
- Vol. 21 (1) , 102930
Epidemiology of major relapse in giant cell arteritis: A study-level meta-analysis